Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-001930-34-DK
EUCTR2005-001930-34-DK
Active, not recruiting
Not Applicable

eft ventricular reverse remodelling after aortic valve replacement in severe valvular aortic stenosis - effect of blockade of the angiotensin-II receptor

Department of Cardiology, Odense University Hospital0 sitesNovember 25, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPatients with severe aortic valve stenosis treated with Aortic Valve Replacement (AVR)
DrugsAtacand (Candesartancilexetil)

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Patients with severe aortic valve stenosis treated with Aortic Valve Replacement (AVR)
Sponsor
Department of Cardiology, Odense University Hospital
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 25, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Department of Cardiology, Odense University Hospital

Eligibility Criteria

Inclusion Criteria

  • •Inclusion criteria
  • •1\.Symptomatic severe AVS referred for valve replacement (mechanic prosthesis or bioprosthesis) at Odense University Hospital
  • •2\.Age \> 18 years
  • •3\.Signed informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Exclusion criteria
  • •1\.Severe renal failure (s\-creatinine \>300 mmole/l)
  • •2\.Moderate or severe hepatic failure (ALAT \>150 IU/l)
  • •3\.Moderate or severe LV systolic dysfunction (LVEF\<40%)
  • •4\.Known intolerance for angiotensin II receptor antagonist (Atacand)
  • •5\.Unwilling to participate in the study
  • •6\.Poor echocardiographic window
  • •7\. Women of childbearing potential (only postmenopausal women)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Imaging of Ventricular Reversed Remodeling after Double Lung Transplantation in Patients with Pulmonary Arterial Hypertensiohigh blood pressure pulmonary arteryIdiopathic/primary pulmonary arterial hypertension1001928010037454
NL-OMON41137niversitair Medisch Centrum Groningen20
Active, not recruiting
Phase 1
Right ventriculAr reverse reModeling and hemodynamic improvement after add-on combination therapy (ambriSentan/PDE-5i) in PAH patientS (RAMSES)patients with pulmonary arterial hypertentionMedDRA version: 21.1Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-004806-32-ITITALIAN PULMONARY HYPERTENSION NETWORK, IPHNET54
Unknown
Phase 3
Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic StenosisAortic Valve StenosisLeft Ventricular HypertrophyAtrial Fibrillation
NCT00294775Odense University Hospital140
Completed
Not Applicable
Right ventricle remodeling after pulmonary valve replacement and percutaneous pulmonary valve insertion, a functional and histopathological assessment.congenital heart diseasepulmonary valve dysfunction10010394
NL-OMON43787niversitair Medisch Centrum Utrecht40
Not yet recruiting
Not Applicable
Improvement in Right Heart Chambers Dimensions After Closure of The Hole in the Heart Chamber Partition WallHealth Condition 1: Q211- Atrial septal defect
CTRI/2024/04/065177AIIMS Delhi Research Section